NCT04569032 2026-02-18A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 ExpressionSeagen Inc.Phase 2 Completed82 enrolled 13 charts
NCT02362997 2026-02-12Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHLDana-Farber Cancer InstitutePhase 2 Completed82 enrolled 20 charts
NCT04447027 2026-01-30Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell MalignanciesNational Institutes of Health Clinical Center (CC)Phase 1 Completed26 enrolled 24 charts